- Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
- Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
- Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
- Harrow Announces New Appointments to its Board of Directors
- Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
- Melt Pharmaceuticals Provides Corporate Update
- Harrow Partners with Leading Healthcare Market Access Technology Platforms
More ▼
Key statistics
On Thursday, Harrow Inc (HROW:NMQ) closed at 13.23, 74.08% above the 52 week low of 7.60 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.76 |
---|---|
High | 13.48 |
Low | 12.70 |
Bid | 13.40 |
Offer | 13.80 |
Previous close | 12.73 |
Average volume | 934.48k |
---|---|
Shares outstanding | 35.36m |
Free float | 30.20m |
P/E (TTM) | -- |
Market cap | 467.85m USD |
EPS (TTM) | -0.7448 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼